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 Introduction
Bacterial infections are the cause of many human and
imal health problems. The latter have a large impact on
r food production, including meat, eggs and dairy. Product
rejection, necessary to avoid human food-borne diseases,
leads to huge economic losses for the farmers. The need to
reduce bacterial infections in the food animal industry
becomes clear in the Food and Agricultural Organization
(FAO) statistical yearbook 2013, reporting an average
annual meat consumption per capita of 80 kg in developed
countries. In 2010, the worldwide meat production totaled
to 3  108 tons (FAO, 2013). In 2011, the New York Times
reported one of the largest meat recalls, being 36 million
pounds of ground turkey, linked to a Salmonella outbreak
where a strain resistant to many commonly prescribed
antibiotics was involved (Neuman, August 4, 2011).
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A B S T R A C T
Bacterial infections in animals impact our food production, leading to economic losses due
to food rejection and the need for preventive and curative measures. Since the onset of the
antibiotic era, the rise of antibiotic-resistant pathogens is causing scares in health care and
food producing facilities worldwide. In the search of new therapeutics, re-evaluation of
bacteriophage (phage) therapy, using naturally occurring bacterial viruses to tackle
infections, is gaining interest. Many studies report about phage therapy success, showing
the value and power of these natural viruses.
Although phages carry some interesting traits and their basic biology is now well
understood, this review argues that phage therapy has not revealed all of its secrets and
many parameters remain understudied, making the outcome of phage therapy highly
variable depending on the disease incidence. These difﬁculties include poorly understood
mechanisms of phage penetration and distribution throughout the body, the variable
expression and accessibility of phage receptors on the bacterial host in in vivo conditions
and the unusual (non-linear) phage pharmacokinetics. These parameters are not easily
measured in realistic in vivo settings, but are nevertheless important hurdles to overcome
the high variability of phage therapy trials. This critical approach is in accordance with
Goethe’s statement; ‘‘Difﬁculties increase the nearer we get to the goal’’. However, since the
importance of the goal itself also rises, both difﬁculties and goal justify the need for
additional in depth research in this domain.
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J. Tsonos et al. / Veterinary Microbiology 171 (2014) 460–469 461The use of lytic bacterial viruses (bacteriophages), being
e natural predators of bacteria, to treat bacterial
fections and its efﬁcient development in the veterinary
ector may therefore have a signiﬁcant economic impact,
specially since antibiotic resistance becomes a major
ublic health crisis. Antibiotic residues in food intended for
uman consumption and the compulsory withholding
eriod to protect human from exposure to antibiotics
ould no longer be a concern if phage therapy is
plemented at large scale. Indeed, phage therapy holds
any intrinsic advantages. Bacteriophages are naturally
ccurring viruses that infect and lyse bacteria. They self-
eplicate exponentially at the infection site and leave the
ommensal ﬂora unaffected because of their narrow
fection spectrum. Their possible autonomous transfer
etween animals could be useful in agricultural applica-
ons (Loc-Carrillo and Abedon, 2011). Because of their
biquitous presence in nature, the isolation of phages
ctive against speciﬁc bacterial strains should be simple.
The concept of phage therapy emerged quickly after the
iscovery of bacteriophages in the beginning of the 20th
entury by Twort and d’Herelle (Inal, 2003). After d’Herelle
etermined the safety of his phage preparation by oral and
ubcutaneous self-administration, he opened the door for
e development of this new kind of therapy. With his
ommercial laboratory in Paris, d’Herelle was the ﬁrst to
troduce bacteriophages as therapeutic agents (Summers,
001; Kutateladze and Adamia, 2008).
The history of phage therapy passed through four
eriods: enthusiasm, skepticism, abandonment and reap-
raisal. Early enthusiasm was generated by a set of
ncouraging results with the ﬁrst ones being obtained
y d’Herelle against ‘‘avian typhosis’’, a gastrointestinal
isease, and bovine hemorrhagic septicemia (Summers,
001). Several pharmaceutical ﬁrms started to sell phage
reparations e.g., Eli Lilly, E.R Squibb and Sons, Antipol and
he German Bacteriophage Society (Fischetti et al., 2006;
ourchesne et al., 2009). The German and Soviet armies
eated their soldiers during WWII against dysentery with
hages (Hermoso et al., 2007). However, this excitement
as short-lived and skepticism against phages as ther-
peutic agents took the lead. A lack of understanding of
asic phage biology, quality control, absence of properly
ontrolled studies and the associated unsuccessful ther-
peutic results contributed to this skepticism (Hanlon,
007; Petty et al., 2007). Also, the discovery of penicillin
aved thousands of Allied soldiers during WWII and its
ass production was further developed in the post-war
ra to cure civilians and contributed to the downfall of
hage therapy in Western medicine (Neushul, 1993). The
ouncil of Pharmacy and Chemistry evaluated phage
erapy in the late 1930s and acknowledged positive
nd negative results. Concern was expressed about the lack
f standardization of phage preparations and the criteria
r purity (Summers, 2001). In 1959, the World Health
rganization came to the conclusion that there were no
easons to continue investigations with phages after the
uccess of tetracycline against cholera (Barrow and
oothill, 1997; Barrow et al., 1998). Unfortunately, because
f the widespread use (and misuse) of antibiotics, bacteria
eveloped antibiotic resistance, in some cases to all
clinically approved antibiotics. The potential of older
methods had to be reexamined, explaining the renewed
interest and reappraisal of phage therapy (Sulakvelidze,
2005).
Basic concepts we nowadays understand were com-
pletely unknown during the early period shortly after the
discovery of phages. The two different replication cycles of
phages (lytic & lysogenic) have now been unraveled and
the importance of the strictly lytic character of phages
(limiting horizontal gene transfer between bacteria) in
therapy is well established. In addition, the high-through-
put sequencing technologies allow inexpensive sequen-
cing, enabling us to assess the presence of genes coding for
factors that increase or generate pathogenicity of the
bacteria or for toxins (e.g., Shiga toxin, cholera toxin,
botulinum neurotoxin) in the phage genome (Wagner and
Waldor, 2002). Phage diversity and speciﬁcity was often
underestimated and led to wrong phage choices for
treatment in the past. Therapists were also not aware of
the highly immunogenic character of the bacterial cell wall
and outer membrane components found in crude phage
lysates, which can lead to severe adverse reactions.
Even if our knowledge on bacteriophages is more
extensive than ever before, the clinical outcome of phage
therapy trials is still variable, indicating that there are still
many parameters which are not yet understood or
controlled. In the past, many attempts to improve the
success of phage therapy have been based on the isolation
of various phages from the environment and the identi-
ﬁcation of those that are the most effective in preventing
mortality from a lethal infection (Levin and Bull, 2004).
However, as will be shown in this review article, many
more aspects are implicated than only the lytic capacity of
phages and their simple administration to an infected
organism.
In this review we outline the parameters which should
be considered when analyzing the efﬁcacy of whole phage
therapy, to prevent the uncertainty and accidental out-
come when going from an in vitro to an in vivo
environment. We discuss the difﬁculties of phage pene-
tration and its inﬂuence on therapeutic success. In
addition, the importance of a detailed knowledge of the
life style of the studied pathogen is highlighted, together
with the too often neglected effect of the unusual phage
pharmacokinetics. Where possible, available information
concerning human phage therapy is mentioned, though
human application remains subject to various (non-
scientiﬁc) limitations (Verbeken et al., 2012). An outline
of the review with the different topics is shown in Table 1.
2. Bacteriophage administration and translocation in
the body
Depending on the site of infection and the method of
administration, phages will need a high or low transloca-
tion capacity to reach the site of infection. At the industrial
scale of intensive animal husbandry, phages must be
administered to the food animals in a non-time-consum-
ing and economically feasible manner. The most straight-
forward administration methods are either orally, by
supplementing the feed or drinking water, or spraying
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J. Tsonos et al. / Veterinary Microbiology 171 (2014) 460–469462ith subsequent inhalation. Topical and systemic delivery
 phages is less straightforward in intensive animal
sbandry systems because they demand an individua-
tic approach. Every infected animal would be treated in
personalized way, which is labor-intensive, time-
nsuming and expensive. Therefore, these administra-
n routes are limited to settings where these tailor-made
atments justify the increased costs, as in the treatment
 valuable purebred animals and pets and in human
edicine.
. Gastrointestinal delivery
Oral administration would be the ideal way to treat
strointestinal infections or colonization, e.g., caused by
mpylobacter and Salmonella. These natural inhabitants of
e gut of livestock are the most common and widely
stributed causative agents of food-borne diseases
cause of meat contamination with intestinal content
ring processing (Carvalho et al., 2012). To reach the
rget site, phages have to pass the acidic environment of
e stomach and the upper small intestine. However,
age have already shown a variable sensitivity against
w pH in vitro (Jamalludeen et al., 2009b). Only one out of
ree lytic coliphages was detected in the duodenum
ove a certain dose (107 PFU) after oral administration
 chickens. This phage could not be detected after 24 h
liveira et al., 2009). In a study on the reduction of
Campylobacter jejuni colonization in young broilers, the
single tested phage was able to remain ‘‘viable’’ while
transiting the gastrointestinal tract, but with an important
reduction in titer. With a daily phage administration (109–
1010 PFU) over a 10-days period in absence of a host, the
detected plaque-forming units (PFU) per gram feces during
this period varied between 103 and 105. Although a
maximal 3 log CFU reduction of C. jejuni could be obtained
during phage administration, the bacterial number
increased rapidly after the last phage dose and stabilized
at a level of colonization only 10 times lower than the
control group not receiving phage treatment (Wagenaar
et al., 2005). Salmonella phages of an orally administered
high titer (3  1011 PFU) three-phage cocktail could be
detected in the caecal content of treated birds at 104 PFU/
g after the 15th day. However, phage identity was not
conﬁrmed, so uncertainty exists about the capacity of all
three phages to reach the caecum. In the timeframe phages
could be detected, the mean CFU in caecal content dropped
about 200 times, while the CFU in untreated birds almost
remained unchanged. When phages could no longer be
detected, an important bacterial load of 2  106 CFU/g
could still be measured (Fiorentin et al., 2005). Even
though phage therapy in the above studies was not able to
completely eradicate the presence of bacteria, the obtained
results can be of importance. A quantitative risk assess-
ment model suggested that a 2 log reduction of Campy-
lobacter in chickens at time of slaughter would be sufﬁcient
ble 1
lective reading table, giving an overview of treatment parameters and highlighted relevant reading.
ey parameters for phage therapy References
hage translocation Administration method Target site
Oral Gut Oliveira et al. (2009)
Wagenaar et al. (2005)
Fiorentin et al. (2005)
Jamalludeen et al. (2009a)
Verthe´ et al. (2004)
McCallin et al. (2013)
Bloodstream Duerr et al. (2004)
Oliveira et al. (2009)
Spray Lungs Huff et al. (2003)
Carmody et al. (2010)
Kvachadze et al. (2011)
indered host receptor binding Caused by
Altered receptors Phase variation Bogomolnaya et al. (2008)
Kim and Ryu (2012)
Enzymatic alternation Mandrell et al. (1990)
Shielded receptors Capsule production Scholl et al. (2005)
Snyder et al. (2004)
Colanic acid production Tuntufye et al. (2012)
Inaccessibility of receptors Intracellular location of pathogen Hsia et al. (2000)
Capparelli et al. (2007)
Broxmeyer et al. (2002)
Hagens and Loessner (2007)
nusual pharmacokinetic properties
Subjected to density-dependent thresholds Bacterial Payne and Jansen (2001)
Capparelli et al. (2007)
Phage Payne et al., 2000
Abedon (2011)
Effect on the model of infection Payne and Jansen (2003)
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osenquist et al., 2003).
To reduce enterotoxigenic Escherichia coli (ETEC)
olonization in pigs, six different phages were individually
rally administered (1010 PFU). Even if some of the phages
d to a signiﬁcant positive weight change, and reduced the
uration and severity of diarrhea, no phages could be
etected with a theoretical detection limit being 103 PFU/g
ces. The mean percentage excretion of the challenge
TEC strain over total E. coli within the phage treated
roups varied between 3% and 37%, compared to 83% in the
ntreated control group. When taking a critical attitude,
e have to admit that the given magnitudes do not
epresent a major decrease in CFUs, even when in some
ases this could be enough to generate a physiological
ffect. With a different model of infection and prior oral
dministration of sodium bicarbonate to neutralize the
tomach’s pH, phages of the three-phage cocktail (109 PFU)
ould be detected in the feces for six days with extremely
arying titers (between 104 and 1011 PFU/g feces) (Jamal-
deen et al., 2009a). Solutions to this decrease in phage
ter may be a higher stomach pH, which can be reached
hen oral phage administration is taking place shortly
fter feeding (Bru¨ssow, 2005). In a study analyzing the
tability of an Enterobacter aerogenes-speciﬁc phage under
imulated gastrointestinal conditions, gastric pH has also
een described as a major barrier when applying phages
rally. At pH 2, the phage concentration dropped
mediately below the detection limit (1  101 PFU/ml).
owever in the reactors, supplemented with antacid
aHCO3), bile salts and pancreatin, there was no
igniﬁcant effect on the phage concentration during the
 h of incubation (Verthe´ et al., 2004).
A ﬁrst human small scale safety study relating to
gestion of a phage cocktail against E. coli and Proteus, was
ecently performed (McCallin et al., 2013). Fifteen healthy
uman subjects of different ages ingested an over-the-
ounter sold Russian phage cocktail. The participants were
iven a high, low and placebo dosage, with a one-week
terval. Although the authors are well aware that delayed
ffects can occur which might therefore be misinterpreted
s an effect of the dosage given, they have not encountered
ny adverse events associated with the phage dosages.
hage administration did not result in phages in the
loodstream and no change in the composition of the
testinal microbiota was observed. However, since the
uthors did not give any detailed information about
resence of phages in feces, it cannot be assumed that
e phages were stable throughout the gastrointestinal
act.
To cure systemic infections following oral administra-
on, phages have to be able to translocate through the
astrointestinal barrier with relatively limited degradation
 reach the peripheral blood and internal organs. In vivo
hage display already showed the necessity of certain
eptide sequences, expressed at the phage surface, to
duce transcytosis across the intestinal barrier. It was
emonstrated that the Enterobacteria phage M13 with
nchanged structural proteins could not be recovered from
e spleen of rats 2 h after gavage with 1012 PFU. M13 with
 modiﬁed minor coat protein pIII, displaying a speciﬁc 7
amino acid sequence insert at the N-terminus, was able to
translocate across the intestine and could be detected
within intestinal mucosal epithelial and submucosal cells,
while the unaltered M13 phage could only be observed in
the intestinal chymus (Duerr et al., 2004). This reﬂects the
possibility of modifying phages to enhance their translo-
cation potential (should the use of modiﬁed phage be
allowed). Apart from this record, there are some studies
showing unmodiﬁed phages capable of passing through
the intestinal wall of animals and humans to ﬁnd their way
to the bloodstream (Oliveira et al., 2009). It remains
unclear whether phage enter the circulatory system via
lymphatic vessels or through diffusion right into the
bloodstream (Keller and Engley, 1958). Rectal administra-
tion seems also a way to deliver phages to the blood
circulation. Penetration of phage to the blood circulation
and urinary tract after oral administration was reported.
Gastrointestinal administration for systemic phage deliv-
ery results in highly variable phage counts in the blood-
stream, making the clinical importance of this
administration route questionable (Weber-Dabrowska
et al., 2000, 2003).
Phages must be able to pass by the immune system
without being cleared. Miernikiewicz and colleagues show
that neither E. coli phage T4 nor its major protein
components affect the production of inﬂammation-related
cytokines in mice, murine dendritic cell cultures or human
blood samples (Miernikiewicz et al., 2013). Although the
study has an in vivo aspect with the murine model, in vivo
human data is lacking. Since this study is limited to the use
of a single phage, it was stated that the human immune
response to other phages has to be investigated, but the
lack of stimulation of the immune system in this study is
the ﬁrst step, and supports the safety of intravenously
administered phages.
2.2. Pulmonary delivery
Nebulizing phage suspensions can be used as an
efﬁcient way to inoculate all animals residing in the same
animal housing. By spraying a phage preparation, ﬁne
droplets are inhaled. For respiratory tract infections, like
avian pathogenic E. coli (APEC), often encountered in
poultry farms, this administration method directly targets
the phage to the infection site. Huff et al. (2003) were able
to reduce the mortality of broiler chicks by spraying a two-
phage cocktail 2 h after APEC inoculation from 50% for
heat-killed phages, to 20% for active phages. The intra-
muscular (i.m.) administration of phages was, in contrast
to spray administration, still effective when given after 24
and 48 h. The researchers speculate that i.m. administra-
tion results in high systemic phage concentrations, which
protect the birds against sepsis, whereas phage aerosols
are not able to generate these protecting phage levels in
blood (Huff et al., 2003). However, i.m. phage administra-
tion is not achievable on industrial production scale. It
seems reasonable to assume that phages could penetrate
the lungs, but conﬁrmation for the presence of phage in the
lungs after i.m. administration is lacking. The outcome of
an intranasal or intraperitoneal phage treatment of a 24 h-
old pulmonary Burkholderia cenocepacia infection was
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J. Tsonos et al. / Veterinary Microbiology 171 (2014) 460–469464alyzed in mice (Carmody et al., 2010). The study showed
at intraperitoneal administration was more effective
an phage inhalation. The researchers did not specify the
act method of nebulization of the phage suspension,
hough a uniform delivery to the lower airways was
imed. At the end of their study, more phages could be
covered from the intranasal-treated mice, but also more
able bacteria (not signiﬁcantly different from untreated
ice) compared to the intraperitoneal treated mice.
traperitoneal injection of phages led to the reduced
esence of bacteria in the lungs, and was therefore the
ore efﬁcient way of administration. The authors sug-
sted that the intraperitoneally administered phages
ere more capable of reaching their host in the lung
renchyma. However, the drop in bacteria was only 1–2
garithmic units, which may not be sufﬁcient for an
fective treatment in severely infected lungs. Never-
eless, the authors identiﬁed intraperitoneal phage
livery as a viable option for the treatment of lung
fections (although this also will depend on economic
asibility).
In a more tailor-made manner, nebulization is used to
at pulmonary diseases in humans. To the best of our
owledge, the only human study describing inhalable
age therapy is a case study reporting the treatment of
aphylococcus aureus and Pseudomonas aeruginosa infec-
n in a cystic ﬁbrosis patient (Kvachadze et al., 2011). The
isting phage cocktail Pyophage was supplemented with
hage speciﬁc against the infecting strain of S. aureus. No
ecise description of the nebulizing method of the phage
spension was provided, nor the administered antibiotic
atment, but the study showed improvement of the
tient’s condition and the absence of adverse effects of
e phage treatment. The ﬁrst clinical trials on larger
oups of subjects remain to be published.
 The in vivo state of bacteria
Assurance of phage receptor expression on the bacterial
ll surface as well as its accessibility in in vivo conditions
of crucial importance to achieve success with phage
erapy. Consequently, the bacterial state in vivo has a
ajor impact on the potential of phage to infect and lyse
em. Phage receptors, which are generally bacterial cell
rface components, enable adsorption and have a key role
 host speciﬁcity. Proteins and/or various lipopolysac-
aride sections (Gram-negative bacteria), peptidoglycan-
ntaining complexes (Gram-positive bacteria), capsular
lysaccharides, pili and ﬂagella can act as receptors
indberg, 1973). The primary requisite for bacteriophage
fection is receptor recognition and successful attach-
ent. This is dependent on the presence and accessibility
 the receptor together with its localization and density on
e cell surface (Rakhuba et al., 2010). Possible modiﬁca-
ns in those parameters as a consequence of the
aptation of the pathogen to the in vivo environment
ill inevitably affect efﬁciency of phage infection. Patho-
ns entering the new environment of the host will react
ith their biochemical sensors to environmental stimuli
d will respond by triggering a cascade of virulence
ctors which are critical for bacterial growth, survival and
persistence during infection (Finlay and Falkow, 1989;
Mahan et al., 2000). A coordinated expression of those
virulence genes together with regulatory and metabolic
genes is needed. Bacteria-phage interactions recurrently
analyzed in vitro may be different in their destined in vivo
environment, especially given the intraspecies variation in
the response to such environments. The complex and
dynamic milieu in animals cannot completely be repro-
duced in vitro. Although certain host environmental
parameters can be mimicked in vitro to induce a subset
of virulence genes, the full repertoire is only expressed in
vivo (Angelichio and Camilli, 2002).
3.1. Altered receptors
Three genes (gtrABC1) have been described in Salmo-
nella enterica serotype Typhimurium to cause ‘form
variation’ upon exposure to eukaryotic cells (macro-
phages), by glucosylation of the O12 antigen generating
the 12-2 variant. Those genes are phase variably expressed
and the 12-2 modiﬁcation is only present on a small
number of cells under bacterial culture conditions. It was
shown that the deletion of one of those genes, with the
associated incapacity of O12-antigen glucosylation, caused
a decreased intestinal persistence when brought in
competition with the wild type strain in Salmonella-
resistant murine models of infection (Bogomolnaya et al.,
2008). Phase variation is a gene regulation process which
has been proposed to facilitate bacterial adaptation in a
rapidly changing environment. Salmonella phage SPC35,
for which it was shown that the O12-antigen of
S. typhimurium assist the binding to its receptor BtuB
during the initial phage adsorption step, is not able to
infect Salmonella cells when the gtrABC1 genes are
expressed (Kim and Ryu, 2012). Another report describes
the physical presence of a component in vivo that induces
enzymatic alternation of surface components. For exam-
ple, the human pathogen Neisseria gonorrhoeae has an
altered lipopolysaccharide in human serum, conferring
serum resistance. The lipopolysaccharide is sialylated by a
pathogen-encoded sialyltransferase in presence of cytidine
monophospho-N-acetylneuraminic acid (CMP-NANA),
which is present in blood. Because N. gonorrhoeae is not
able to synthesize CMP-NANA and it is not present in the
standard media, in vitro studies may have dealt with
different lipopolysaccharide structures than those occur-
ring in vivo (Mandrell et al., 1990).
3.2. Shielded receptors
Besides modiﬁcation of the receptors, some bacteria
shield their receptors against several phages through the
production of extracellular polysaccharides that act as
physical barrier. It has been demonstrated that the
lipopolysaccharide-recognizing phage T7, is blocked from
receptor adsorption by the exopolysaccharide K1 capsule
in a K1-producing K12 E. coli strain (Scholl et al., 2005). The
regulation of genes can be analyzed in vivo with the use of
various technologies, including recombination-based in
vivo expression technology (RIVET). Tuntufye et al. (2012)
identiﬁed thereby wcaJ as a gene speciﬁcally expressed
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J. Tsonos et al. / Veterinary Microbiology 171 (2014) 460–469 465uring systemic infection of APEC (avian pathogenic E. coli)
 chickens. Its gene product is involved in the biosynthesis
f an exopolysaccharide (colanic acid), forming a thick
ucoid matrix on the cell surface (Tuntufye et al., 2012).
he transcriptome of uropathogenic E. coli (UPEC) isolated
om the urine of infected mice revealed a high upregula-
on of genes involved in capsular polysaccharide synthesis
nyder et al., 2004). Capsule formation is often a virulence
ctor helping the pathogen to escape phagocytosis by the
mune system (Finlay and Falkow, 1989).
.3. Inaccessible pathogen
The intracellular form of some pathogens may also
inder traditional phage therapy, since phages must gain
ccess to the intracellular location. This is especially the
ase for obligate intracellular parasites such as Chlamydia
sittaci where the extracellular form is metabolically inert.
hages need for their replication metabolically active
acteria to avail host energy and biosynthesis. Transmis-
ion electron microscopy analysis demonstrated that co-
ternalization of the lytic phage wCPG1 occurred during
ukaryotic incursion (HeLa cells), while they were attached
 metabolically dormant elementary bodies of C. psittaci
sia et al., 2000). Infection of the pathogen in the
ukaryotic vacuoles only took place after differentiation
 an active bacterial form, with an abundant release of
hage progeny after presumed phage-induced lysis. This
bservation of phage co-internalization has also been
escribed during S. aureus infection of mouse peritoneal
acrophages. The amount of intracellular bacteria could
e reduced in vitro after treatment with phage-infected
acteria (i.e., phage adsorbed to S. aureus by preincuba-
on). No reduction after treatment with phage alone could
e observed (Capparelli et al., 2007). With the demon-
trated need of a phage delivery vehicle to treat infections
hich have an intracellular form of life, a non-pathogenic
ycobacterium smegmatis strain has been proposed as
phage carrier’’ to reduce the intracellular numbers of
athogenic Mycobacterium avium. An in vitro 100-fold
ecrease of the pathogens present in infected macrophages
as observed. The mechanism of phage TM4 delivery was
bserved by light-microscopy and showed the fusion of a
acuole containing M. smegmatis-TM4 with a vacuole
ontaining M. avium (Broxmeyer et al., 2002). Because of
e intracellular life style of Listeria monocytogenes during
fection of the mammalian host, it has already been stated
at classical phage therapy will be impossible in the
eatment of the disease (Hagens and Loessner, 2007).
owever, Listeria phages are used as a preventive measure
s food additive in high-risk foods, cf. ListexTM and
istShieldTM (Hagens and Loessner, 2007).
These ﬁndings highlight the need for a thorough
nderstanding of the state and location of the targeted
acterium to adapt the phage treatment and angle of
ttack consequently.
. Speciﬁc pharmacokinetic properties
A reason for diverse and unpredictable outcome when
pplying phages for therapeutic purposes has been argued
by a lack of appreciation of the extent to which
pharmacokinetics of phages differ from traditional mole-
cule drugs. To enhance the successful outcome of phage
therapy, a good understanding of the (non-linear) kinetics
of bacteriophages as self-replicating pharmaceuticals is
necessary, so that at least bacterial killing is theoretically
likely when designing therapeutic protocols (Levin and
Bull, 2004; Abedon, 2011). The best phage dosing, time of
administration and choice of single/multiple administra-
tions can be theoretically approached following computer
simulations. Simple kinetic models, describing the rate at
which the bacterial and phage concentrations evolve, rely
on certain independently measurable biological para-
meters, the most important being adsorption rate, burst
size, latent period (i.e. time between infection and lysis),
phage decay rate and growth rate of bacteria (Payne and
Jansen, 2003; Abedon, 2011). Some kinetic models
incorporate parameters for bacterial resistance (mutation
rate) and natural effects of the host, including the immune
response (Payne and Jansen, 2001; Cairns et al., 2009). An
estimation of some of these parameters is made following
in vitro analysis. It must be emphasized that those phage-
bacteria interactions and the properties of phage and
bacteria are likely to differ in vivo (Cairns et al., 2009), e.g.,
phage and bacterial titers seemed to be more stable in
gastric juices with pH 2.0, compared to Lysogeny Broth
with corresponding pH (Weld et al., 2004).
The applicability of simple generic growth models to a
heterogeneous, less ﬂuid environment of the digestive
tract system of rats was tested. Those models were ﬁtted in
a crude approximation ﬂow model to predict the bacterial
and phage number evolution in the caecum. Those were
compared to experimental data, where rats received orally
a bacterial dose followed by a phage dose. For one of the
tested phages (K1-5), the prediction of phage titer is in
good agreement with the experimental data, even if the
applied phage growth parameters were determined in vitro
on exponentially growing bacteria. However, the bacteria
were not eliminated in vivo in contrast to the simulation.
Also, the second tested phage (T4) showed an in vivo
growth deﬁciency with the predictions being far from the
observed phage titers (Weld et al., 2004).
The models do not pretend to ensure successful
therapeutic outcome of phage therapy trials but have to
be considered as exploratory guidelines during phage
choice, experimental design and result interpretation of in
vivo tests.
4.1. Existence of density-dependent thresholds
Treatment outcome has been described by Payne and
Jansen as being subjected to various density-dependent
threshold effects (Payne and Jansen, 2001). The prolifera-
tion threshold, which is unique to phage therapy because
of its self-replicating character, is of central importance in
active phage therapy. A treatment is said to be active when
it relies on phage replication in situ to achieve bacterial
control (Curtright and Abedon, 2011). For active phage
therapy, implying a net increase in phage numbers, a
minimal bacterial concentration (proliferation threshold)
is needed to ensure such a contact frequency that the rate
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e lost. The proliferation threshold is dependent on phage
d bacterial characteristics and highlights the importance
 the time point of phage administration (Payne and
nsen, 2003). Ideally, active treatment should be given at
e moment when bacterial densities reach a value where
t phage increase can start, which is the proliferation
set time (Tp). This is paradoxical when one compares it
 antibiotics, where treatment has to be given as early as
ssible. Evidently, treatment shouldn’t be administered
o late, since mortality could in this case result from an
eversible, extreme toxin production or tissue damage by
e pathogen (Bull et al., 2002). When an antibiotic is
mbined with a phage treatment, the effect of active
erapy will, in accordance to those models, be reduced if
is not attained because of antibiotic-induced bacterial
lling (Payne and Jansen, 2003). This is of relevance in
man phage therapy trials, where because of ethical
asons, phages are in almost all cases administered in
mbination with antibiotics. To administer the phage
atment at Tp, when active treatment wants to be
hieved, is however even more complex when consider-
g the different stages of infection in real circumstances at
population level, i.e. in cases where animals are kept in
gh volume housing.
Using an experimental approach, this bacterial density
reshold where active treatment can take place, was
und to be approximately 104 CFU/ml in kidneys, spleen
d heart of mice infected with S. aureus. In the blood-
eam this threshold was not achieved and no net phage
crease could be noticed (Capparelli et al., 2007). The
mous experiment of Smith and Huggins (1982) achieved
more effective treatment using a single anti-K1 phage
se than multiple doses of antibiotic. This was linked to a
ong active in vivo replication (Smith and Huggins, 1982).
is implies a low and easily surpassed proliferation
reshold (Payne and Jansen, 2001). The importance of
od timing on the outcome of a successful treatment has
us been observed, but until now successful phage
erapy is in many studies related to an early phage
ministration instead. This could be, for example, be
ustrated by the subcutaneous infection of mice with
brio vulniﬁcus, a human opportunistic pathogen, where
timum protection required phages to be administered
traveneously) within 3 h of bacterial inoculation (Cer-
ny et al., 2002). Furthermore, immediate treatment
uld be necessary in those cases where a local infection
olves to a general infection. Treatment of poultry
ffering from experimentally induced severe E. coli
spiratory infection with an aerosol phage spray showed
decrease in mortality when phage was administered
mediately after infection, while only minor treatment
ﬁcacy was obtained when phage were given after 24 or
 h (Huff et al., 2003). A reduction in mortality in a mouse
odel infected by Salmonella could only be obtained for a
rtain oral treatment schedule, with the earliest (hours
st infection) the most efﬁcient, while other treatments
ays post infection) only delayed the death of the mice
ardina et al., 2012).
Besides bacterial density, the administered phage
antity is also highly important for the outcome of phage
therapy. For phage therapy likely to be effective, the dose
of phage present at the infection site must be higher than
the inundation threshold, the concentration of free phage
inducing a reduction in bacterial amounts (Payne et al.,
2000; Payne and Jansen, 2001). This threshold can be
reached immediately or can be delayed in time because of
in situ phage replication (if conditions enable active
therapy). As deduced from mathematical models, it has
been described as being the ratio of the rate of bacterial
replication over the rate of phage adsorption (Abedon,
2011). As stated by Abedon, this is a metric that is difﬁcult
to determine in situ and can only avoid that chosen phage
densities are far too low to achieve desired levels of phage
therapy efﬁcacy (Abedon, 2011). This can easily be
illustrated by many studies, one of them being the
recovery of 5/5 mice after intravenous treatment with
109 PFU Staphylococcus phages, compared to 100% deaths
with a dose of 107 PFU (Capparelli et al., 2007).
If conditions do not enable active therapy, a continuous
delivery of concentrated phages will be needed. Passive
treatment supplies sufﬁciently high phage densities,
without relying on in situ phage replication. Under these
circumstances the larger and the earlier the dose of phage
the better (equivalent to conventional drugs). However, for
certain pathologies, phage will need the capacity to
translocate to reach the bacterial reservoir in sufﬁciently
high numbers to reduce the rate of replication of infecting
bacteria, which can be difﬁcult to achieve (see above).
4.2. Importance of the model of infection
When designing an animal experiment attention must
be paid to the natural host time scale. This is the time point at
which an untreated animal would recover or die. Active
therapy can only be feasible if the proliferation onset time
(Tp) is smaller than the natural host time scale. If the
pathogen is too virulent and the animal dies at low bacterial
load, even before Tp could be reached, effective active
therapy will theoretically be impossible. In this case only
passive therapy can be applied. From the other side, the
efﬁcacy of an active treatment can also not be assessed if the
animal recovers before Tp is reached (Payne and Jansen,
2003). Active therapy will fail when tested on models of
infection with a too low bacterial infection dose or rapid
bacterial dissemination in the animal’s body, inducing too
low bacterial densities accompanied by a bad timing of
phage administration (and too low titer). These principles
should be kept in mind when the bacterial strain and the
bacterial inoculum size are chosen to assess the efﬁcacy of a
phage (cocktail) in experimentally infected animals.
Successful in vivo experiments in experimental animal
models may, however, not guarantee success of phage
therapy under realistic conditions, where bacterial den-
sities cannot be monitored in real time, especially given the
natural variation of virulence among strains of the same
species.
5. Conclusion
This review on natural bacteriophage therapy was
made with the objective to highlight some points which
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J. Tsonos et al. / Veterinary Microbiology 171 (2014) 460–469 467re not yet properly understood. Some factors are crucial
r the outcome of phage therapy and should not be
nderestimated. Hurdles caused by the intrinsic nature of
e phage need to be overcome. We are still at a stage
here a strong variability exists on the outcome of whole
hage therapy. The view on its success may be biased from
e fact that most negative results remain unpublished.
he most, and maybe only, critical view on phage therapy
as been described in articles reporting the peculiar
inetics of these self-replicating pharmaceuticals. Payne
nd co-workers commented the studies on bacteriophage
erapy as having a history of being rather hit-or-miss.
hages that actively replicate and lyse bacteria in vitro do
ot always do so in vivo explaining the high variability of
erapeutic outcome of whole phage administration after
fection (Payne et al., 2000).
Whole phage therapy certainly has potential as a
eatment in speciﬁc areas. Its efﬁciency has been reported
 several cases and several companies are undertaking the
ommercialization of bacteriophages. Intralytix Inc. pro-
uces besides phage preparations for food application
istShieldTM against Listeriosis, EcoShieldTM against E. coli
157:H7, SalmoFreshTM against salmonellosis), bacter-
phage-products for veterinary applications (PLSV-1TM
gainst Salmonella and INT-401TM against Clostridium
erfringens in poultry) and two human therapeutic
roducts which are in various stages of development.
icreos has commercialized LISTEXTM against L. mono-
ytogenes as a food processing-aid and several trials
elating to animal health are ongoing. AmpliPhi is
nalyzing phage mixtures in the preclinical stage for
uman and animal therapy.
The hurdle of translocation is not present in case of
pical phage delivery and its applicability is therefore less
omplicated. Phages have shown to be promising ther-
peutics in the treatment of burn wounds. Often,
ntibiotics are not capable of reaching burn wound beds
 sufﬁcient high concentrations to clear bacterial infec-
ons. PhagoBioDerm, a biodegradable polymeric compress
pregnated with bacteriophages, was licensed for sale in
e Republic of Georgia in 1999, and a complete recovery
r improvement of clinical symptoms in almost 95% of the
atients was reported (Markoishvili et al., 2002). However,
ince 1999 there has been no widespread distribution of
e product. Marza and colleagues report a successful case
tudy of phage treatment applied on burn wounds
olonized with P. aeruginosa (Marza et al., 2006). Ten pet
ogs with difﬁcult to clear, antibiotic-resistant otitis
aused by P. aeruginosa were treated with a six-phage
ocktail (Hawkins et al., 2010). Two days after phage
dministration, bacterial counts fell in all cases, whereas
hage counts were higher than the initial administered
ose.
The more translocation is necessary for phages to reach
eir infection site, the more hurdles they will need to
vercome. Depending on their characteristics, variable
umbers of phages will arrive at the end of this obstacle
ourse and will or will not reach the target infection site.
or this, a good phage selection and corresponding titer
ill be important to bring at the infection site the minimal
be effective. To achieve successful active phage therapy,
one should take into account many complex parameters
which are hard to determine for in vivo situations. For this
reason passive therapy seems to be more likely to be a good
ﬁrst option of treatment. Especially in this last case, if
highly concentrated phages are required for treatment, one
should evaluate the technological capacity to achieve such
high concentrations and associated costs for production.
Intramuscular phage administration has already shown to
deliver higher phage levels in the blood, which in case of
systemic infections will be more able to diminish bacterial
load (Huff et al., 2003). Such treatments are on industrial
production scale less easily feasible or even not con-
ceivable, e.g. in poultry farms. Limitations following
restrictions in time and cost in the food animal production
sector will need adapted treatments.
Because of the difﬁculty to predict the in vivo efﬁcacy
based on in vitro results, as stated above, Henry and
colleagues proposed a method to assess the therapeutic
potential of phages based on a real-time imaging system in
a mice lung infection model. Two of the nine individually
tested phages, with in vitro activity, did not show the
expected in vivo therapeutic capacity to rescue infected
animals in similar conditions. One of them had therapeutic
effect after increasing the phage dose (cf. kinetics), the
other one when a different bacterial infection strain was
used (cf. bacterial state in vivo). By paralleling the evolution
in bacterial bioluminescence with the proportion surviving
bacteria, a model was developed whereby bacteriophages
could be discriminated based on their in vivo efﬁcacy after
8 h. The development of such models would contribute in
the rapid screening of therapeutic efﬁcient phages in vivo
(Henry et al., 2013).
Further analysis of these and other domain-speciﬁc
parameters, will allow to determine the limitations and the
applicability of phage therapy.
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